Haemonetics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending March 29, 2025: 14.15%

Haemonetics Corporation EBIT Margin is 14.15% for the Trailing 12 Months (TTM) ending March 29, 2025, a 3.57% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Haemonetics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending March 30, 2024 was 13.66%, a 2.35% change year over year.
  • Haemonetics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending April 01, 2023 was 13.35%, a 64.38% change year over year.
  • Haemonetics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending April 02, 2022 was 8.12%, a -21.22% change year over year.
  • Haemonetics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending April 03, 2021 was 10.31%, a -1.39% change year over year.
Key Data
Date EBIT Margin EBITDA Margin Net Income Margin EBT Margin